People suffering from post-traumatic stress disorder often can’t face their trauma, which is necessary for psychotherapy to work. It is a big reason PTSD is so difficult to treat. Scientists are leading clinical trials into the use of the banned drug MDMA in connection with therapy to help break this hurdle, and the results so far have been outstanding in curing PTSD.
Two experts from the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation join Radio Health Journal to discuss the latest research into using MDMA for PTSD and if it could become a mainstream form of treatment.
- Dr. Michael Mithoefer, Clinical Assistant Professor of Psychiatry, Medical University of South Carolina and Medical Director, MAPS Public Benefit Corporation clinical trials
- Charlotte Harrison, Senior Clinical Research Associate, MAPS Public Benefit Corporation